Medtech Startups to Watch: Five Standout Innovators from LSI Asia ’26

Every LSI event brings together dozens of companies developing new medical technologies, but a handful always leave a particularly strong impression. Following LSI Asia ‘26 in Singapore, LSI’s Market Intelligence team reviewed presentations from more than 70 companies to identify five medtech startups that stood out based on their technology, commercial potential, recent milestones, and the markets they are pursuing.

One trend became immediately apparent. Many of this year’s most compelling innovators came from across the Asia-Pacific region, demonstrating that companies headquartered in Singapore, China, and Thailand are increasingly building technologies designed for global adoption rather than regional markets alone.

Below are five companies that captured our attention and the market dynamics supporting each opportunity.

Aqua Medical

Aqua Medical is developing an endoscopic treatment designed to address type 2 diabetes through a minimally invasive procedure instead of lifelong drug therapy.

Its RFVA platform enables PIMA (Proximal Intestinal Mucosal Ablation), an outpatient procedure that ablates 50 to 70 centimeters of the proximal intestine to restore metabolic signaling that drives type 2 diabetes. The approach requires no implants, no surgical incisions, and no ongoing medication.

Clinical progress has been encouraging. Aqua Medical has treated 66 patients, received FDA Breakthrough Device Designation, and secured FDA IDE approval in late 2025 for its U.S. type 2 diabetes pilot study. At Digestive Disease Week 2026, the company reported an average A1C reduction of approximately 2.1% while achieving complete insulin elimination after 12 months in a 20-patient cohort. Aqua Medical also holds FDA 510(k) clearance for Barrett’s esophagus, providing an established regulatory foundation as its diabetes program advances.

The opportunity is significant. Approximately 38 million Americans live with diabetes, with 90 to 95% diagnosed with type 2 disease, while the International Diabetes Federation estimates roughly 589 million adults worldwide are affected.

Rather than replacing GLP-1 therapies, Aqua Medical’s technology could complement them by offering a durable procedural option for patients who cannot tolerate, afford, or remain on long-term drug therapy.

2Strands Biosciences

Singapore-based 2Strands Biosciences is focused on making molecular residual disease monitoring more broadly accessible through its blood-based ctDNA test, Recura.

The company’s proprietary allele-enrichment sequencing approach is designed to detect variant allele frequencies as low as 0.001%, approaching the performance of leading institutional liquid biopsy platforms while targeting a substantially lower cost.

2Strands has completed the NUS Medicine accelerator, participated in MedTech Innovator Asia Pacific 2025, and closed a pre-seed financing led by Elev8 VC. The company plans to raise a Seed round during Q4 2026 as it advances Recura toward Laboratory Developed Test status in the United States.

The broader liquid biopsy market was valued at approximately $6 billion to $10 billion in 2024 and is projected to reach roughly $22 billion to $31 billion by the mid-2030s. Molecular residual disease monitoring represents the fastest-growing segment, with the U.S. MRD testing market estimated at about $874 million in 2024.

Because serial ctDNA testing has demonstrated the ability to detect recurrence months before conventional imaging, reducing testing costs could become an important driver of wider clinical adoption.

magAssist

Suzhou-based magAssist represents another trend that has become increasingly visible across the medtech landscape: Chinese innovators entering highly sophisticated device categories traditionally dominated by Western manufacturers.

The company’s portfolio centers on magnetic levitation pump technology for mechanical circulatory support. Its flagship product, NyokAssist, is an interventional ventricular assist device that the company describes as the world’s smallest pVAD. It received FDA Breakthrough Device Designation in 2023, becoming the first interventional cardiac device developed in China to earn the designation.

More than 160 patients have already enrolled in the company’s planned 240-patient China pivotal study. Meanwhile, both MoyoAssist and the BreathMo ECMO system have received NMPA approval and are entering commercial rollout.

Compass AI shows magAssist has raised approximately $124.2 million to date, including a recent $46.2 million financing, and the company is currently seeking up to an additional $100 million.

Mechanical circulatory support remains one of medtech’s most protected franchises, particularly within pVADs. For that reason, magAssist represents an emerging competitive force that industry strategics will likely continue monitoring closely.

Meticuly 

Thailand’s Meticuly is rethinking how personalized implants are produced and delivered.

Using AI-driven design, the company manufactures patient-specific titanium implants for cranial, craniofacial, and orthopedic procedures. It also became the only company to receive FDA clearance covering both patient-specific titanium cranioplasty implants and the associated manufacturing workflow.

Its Factory-in-a-Box model allows hospitals to design, manufacture, sterilize, and deliver implants locally, reducing production timelines to just one or two days. Working alongside Siriraj Hospital, Meticuly became one of the first organizations worldwide to manufacture regulatory-compliant titanium implants directly at the point of care. In 2025, the company also delivered an on-site 3D-printed hip implant.

Commercial momentum includes more than 2,600 clinical cases across 260 hospitals, over 200% core revenue growth during 2025 driven by U.S. expansion, more than four FDA pipeline products, over 80 intellectual property assets, and a 2024 WIPO Global Award.

Rather than focusing solely on implant design, Meticuly’s distributed manufacturing model addresses one of personalized medicine’s biggest logistical challenges by bringing production directly to hospitals.

PEDRA Technology

Singapore-based PEDRA Technology has developed an FDA Breakthrough Device-designated tissue perfusion monitoring platform for peripheral artery disease and limb-threatening ischemia.

Current clinical decision-making often lacks reliable real-time information about tissue perfusion following revascularization. PEDRA’s technology aims to provide that missing data at the point of care, helping clinicians make better-informed treatment decisions before irreversible tissue damage occurs.

The company is currently conducting a 50-patient clinical study supported by the Temasek Foundation.

Peripheral artery disease affects an estimated 200 million people globally, while limb-threatening ischemia carries mortality rates approaching 20% within six months and remains a leading cause of non-traumatic amputations, particularly among patients with diabetes.

PEDRA estimates its addressable opportunity at roughly a $6 billion peripheral vascular market. Clinically and economically, technologies that help preserve limbs can reduce downstream costs associated with amputation, prosthetics, rehabilitation, and long-term disability.

Looking Ahead

Selecting only five companies from more than 70 presentations was no easy task, and many deserving innovators could easily have made this list. Even so, these medtech startups highlight several themes emerging across Asia, including procedural innovation, precision diagnostics, AI-enabled manufacturing, cardiovascular technologies, and improved clinical decision support.

As LSI’s global event series continues, we expect to see many more innovators building on this momentum when the community reconvenes at LSI Europe ’26 in Barcelona later this year.